Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice
- 31 March 2005
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 85 (1-2), 107-114
- https://doi.org/10.1016/j.tube.2004.09.013
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse modelClinical and Experimental Immunology, 2004
- Immunization with heat-killed Mycobacterium bovis bacille Calmette–Guerin (BCG) in Eurocine™ L3 adjuvant protects against tuberculosisVaccine, 2003
- A marked difference in pathogenesis and immune response induced by differentMycobacterium tuberculosisgenotypesClinical and Experimental Immunology, 2003
- Mycobacterium tuberculosis arabinomannan–protein conjugates protect against tuberculosisVaccine, 2003
- Boosting Vaccine for TuberculosisInfection and Immunity, 2001
- Tuberculosis vaccine development: recent progressTrends in Microbiology, 2001
- Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in MalawiThe Lancet, 1996
- Variation in protection by BCG: implications of and for heterologous immunityThe Lancet, 1995
- Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literatureJAMA, 1994
- Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, ChileTubercle and Lung Disease, 1992